Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs

Gastroenterology

Volumn 125, Issue 2, 2003, Pages 389-395

  Laine, Loren ^a   Wogen, Jenifer ^b   Yu, Holly ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Institute for Effectiveness Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DATA BASE; DRUG COST; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; UNITED STATES;

EID: 0042667002     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00900-4     Document Type: Article

References (17)

1. Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology 2001;120:594-606.
2. Rahme E, Joseph L, Kong SX, Watson KJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-924.
3. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1986;84(suppl 2A):20-24.
4. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-469.
5. Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, Dreyer NA. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-1481.
6. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology 1999;117:776-783.
7. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999;282:1921-1928.
8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
9. Laine L, Bombardier C, Reicin A, Hawkey C, Watson DJ, Ramey DR, Brett C. Gastrointestinal (GI) co-therapy, procedures, and hospitalizations in a GI outcomes study of rofecoxib vs naproxen in rheumatoid arthritis. Am J Gastroenterol 2000;95:2633 (abstr).
10. Goldstein JL, Eisen G, Stenson W, Agrawal N, Burke T, Pettitt D, Wilson AM, Fort J. Celecoxib significantly reduces gastrointestinal-related healthcare resource utilization compared to NSAID: SUCCESS-1 in ostearthritis (OA) trial (abstr). Am J Gastroenterol 2001;96(suppl):S268.
11. Zhao Z, Boscarino JA, Deverka PA, Epstein RS, Wang Chin J. Predicting drug spending: update and evaluation of a revised chronic disease score. Presented at ISPOR Fifth International Meeting, May 2000.
12. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon G. A chronic disease score with empirically derived weights. Med Care 1995;33:783-795.
13. Efron B, Tibshirani RJ. An introduction to the bootstrap, New York: Chapman and Hall, 1993.
14. Bjarnason I, Hayllar H, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-1847.
15. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998;25(suppl 51):8-16.
16. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C. Serious lower GI clinical events with non-selective NSAID or coxib use. Gastroenterology 2003;124:288-292.
17. FDA Arthritis Advisory Committee meeting. February 7, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm. Accessed June 16, 2003.